Several clinical trials evaluate the application and observational outcomes of prasugrel in patients with acute coronary syndrome, acute myocardial infarction, heart failure, and concurrent type 2 diabetes. Sponsored by diverse academic and healthcare entities—including University Hospital Heidelberg, AstraZeneca, Tabula Rasa HealthCare, and Chiesi Farmaceutici S.p.A.—the portfolio includes both completed observational registries and actively recruiting trials. Although formal trial phases are unspecified, these studies examine real-world eligibility, comparative antiplatelet regimens, and treatment outcomes in patients undergoing percutaneous coronary intervention.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05774431 | Recruiting | Acute Myocardial Infarction |
University Hospital Heidelberg|AstraZeneca |
2023-03-13 | -- |
| NCT05053828 | Completed | Type2 Diabetes|Antiplatelet Drugs|Myocardial Infarction|Heart Failure |
Tabula Rasa HealthCare |
2021-09-20 | -- |
| NCT04471870 | Completed | Acute Coronary Syndrome |
Chiesi Farmaceutici S.p.A. |
2020-10-23 | -- |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).